Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537414
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Study of Sequential Therapy With DaplusiranTomligisiran DAPTOM Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B CHB
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2b Multi-centre Randomized Partially Placebo-controlled Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With DaplusiranTomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background NucleostIde Analogue Therapy B-United
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
B-UNITED
Brief Summary:
The study is intended to evaluate the efficacy and safety of 2 different doses of DAPTOM followed by bepirovirsen in participants living with CHB on standard of care nucleostide analogue NA therapy The study also aims to identify an optimal dose of DAPTOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAPTOM to the sequential regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None